Skip to Content

NIH Halts Trial of Convalescent Plasma for Mild COVID-19

WEDNESDAY, March 3, 2021 -- A clinical trial evaluating the use of convalescent plasma in patients with mild to moderate COVID-19 symptoms has been halted because the treatment didn't benefit them, according to the U.S. National Institutes of Health.

Convalescent plasma (also called "survivor's plasma") is derived from the blood of patients who have already recovered from COVID-19. It's thought that infusions of the antibody-rich plasma might give patients an extra weapon to fight off SARS-CoV-2.

The NIH study included patients seen at an emergency department who's had mild to moderate coronavirus symptoms for a week or less.

However, "even if enrollment continued, this trial was highly unlikely to demonstrate that COVID-19 convalescent plasma prevents progression from mild to severe illness" in at-risk patients who seek emergency care but are not hospitalized, an NIH news release said.

The trial to assess the safety and effectiveness of the therapy began in August and included 47 emergency departments nationwide. Of the 900 adult patients it sought to recruit, 511 were enrolled before the trial was halted. Patients had at least one risk factor associated with severe COVID, such as obesity, high blood pressure, diabetes, heart disease or chronic lung disease. But when they arrived at the ER, none were sick enough to be hospitalized.

Study participants received either convalescent plasma or a placebo. They were then followed to assess three outcomes: If they sought further emergency or urgent care, if they had to be hospitalized, or if they died within 15 days of entering the trial.

While the study found the treatment to be safe, the researchers found no significant differences in the three outcomes between those who received the COVID-19 convalescent plasma or the placebo.

An independent monitoring board recommended halting the trial after a Feb. 25 meeting, and the study stopped enrolling new patients.

Based on earlier studies that suggested convalescent plasma might be of benefit, more than 100,000 people in the United States and many more worldwide have been given the therapy since the pandemic began.

The findings contrast with a small Argentinian study of 160 elderly patients who were infected but not yet sick enough to be hospitalized. That study, published in January in the New England Journal of Medicine, concluded that convalescent plasma could help prevent severe illness in older patients who were newly infected with coronavirus.

Researchers in that study said two factors were key: Donor plasma had to be given within 72 hours of the start of symptoms, and the plasma must have a high concentration of antibodies.

© 2021 HealthDay. All rights reserved.

Read this next

Lots of Teens, Young Adults Are Helping to Care for Older Loved Ones

TUESDAY, April 20, 2021 – Many people regard middle-aged caregivers as the "sandwich generation" — folks caring for young kids as well their aging moms, dads or...

'Double-Masking' It? Proper Fit Is Crucial, Study Finds

TUESDAY, April 20, 2021 -- Wearing two snug, well-fitted face masks can significantly reduce your risk of coronavirus infection, researchers say. But a good fit is key: The new...

Meatpacking Plants Accounted for 334,000 U.S. COVID Cases: Study

TUESDAY, April 20, 2021 -- Meatpacking plants were the source of an estimated 334,000 COVID-19 cases in the United States, according to a new study. It puts the economic toll...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.